NFKB1 and cancer: Targeting NF-κB-mediated survival mechanisms, such as treatment with survivin inhibitors (YM155) combined with TRAIL or γ-radiation, has shown promise in sensitizing resistant cancers to apoptosis, highlighting its therapeutic relevance [265].